Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bristol Myers Squibb (BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company dedicated to developing innovative therapies for ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.